Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low-risk Myelodysplastic Syndromes”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT00458159
What this trial is testing

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndrome
Celgene 34
Testing effectiveness (Phase 2)Ended earlyNCT01459159
What this trial is testing

Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome (MDS)
Telik 162
Early research (Phase 1)Looking for participantsNCT07283094
What this trial is testing

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Montefiore Medical Center 33
Early research (Phase 1)Looking for participantsNCT05636514
What this trial is testing

Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS

Who this might be right for
Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaAcute Myeloid Leukemia
Clinical Hub for Interventional Research (CHOIR) 12
Testing effectiveness (Phase 2)Study completedNCT00700206
What this trial is testing

Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome (MDS)
Telik 86
Not applicableStudy completedNCT01739452
What this trial is testing

Spanish Registry of Erythropoietic Stimulating Agents Study

Who this might be right for
Myelodysplastic Syndrome
Grupo Español de Síndromes Mielodisplásicos 722
Testing effectiveness (Phase 2)Study completedNCT00067808
What this trial is testing

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center 128
Testing effectiveness (Phase 2)UnknownNCT00513578
What this trial is testing

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
The Vaccine Company 30
Not applicableNot Yet RecruitingNCT07752121
What this trial is testing

First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms

Who this might be right for
Myelodysplastic Neoplasms
Bristol-Myers Squibb 190
Not applicableStudy completedNCT00789256
What this trial is testing

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic Syndromes
Dartmouth-Hitchcock Medical Center 26
Large-scale testing (Phase 3)Ended earlyNCT00695396
What this trial is testing

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Who this might be right for
Myelodysplastic SyndromesAnemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 25
Testing effectiveness (Phase 2)Looking for participantsNCT07249346
What this trial is testing

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Who this might be right for
LeukemiaMyelodysplasiaChronic Myelomonocytic Leukemia
Hannah Choe, MD 124
Testing effectiveness (Phase 2)Study completedNCT00571662
What this trial is testing

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

Who this might be right for
Acute Myelogenous LeukemiaAcute Lymphocytic LeukemiaChronic Myelogenous Leukemia+6 more
University of Nebraska 76
Testing effectiveness (Phase 2)Study completedNCT01444742
What this trial is testing

Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
LeukemiaMyeloproliferative Diseases
M.D. Anderson Cancer Center 81
Testing effectiveness (Phase 2)Study completedNCT01995578
What this trial is testing

Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Who this might be right for
Myelodysplastic Syndromes (MDS)Acute Myelogenous Leukemia (AML)
Memorial Sloan Kettering Cancer Center 32
Large-scale testing (Phase 3)Looking for participantsNCT06499285
What this trial is testing

Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Who this might be right for
Myelodysplastic Syndromes
Takeda 225
Testing effectiveness (Phase 2)Ended earlyNCT00495547
What this trial is testing

SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
PETHEMA Foundation 16
Testing effectiveness (Phase 2)WithdrawnNCT01302106
What this trial is testing

Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Testing effectiveness (Phase 2)Ended earlyNCT02599649
What this trial is testing

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 10
Testing effectiveness (Phase 2)Study completedNCT00382590
What this trial is testing

Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic SyndromeLeukemia
M.D. Anderson Cancer Center 11
Next Page